Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage.
The Chinese trial tested ivonescimab and chemotherapy against…
